The liver has a vital role in many metabolic and regulatory processes in the body. Primary biliary cholangitis (PBC), pre-viously known as primary biliary cirrhosis, is a chronic choles-tatic autoimmune disease of the intrahepatic bile ducts asso-ciated with loss of tolerance to mitochondrial antigens. At this time there is no definitive cure for PBC; however, ursodeoxy-cholic acid (UDCA) has been shown to reduce injury when ad-ministered as the first line of treatment. Additional therapeu-tics can be given concurrently or as an alternative to UDCA to manage the symptoms and further curb disease progression. Currently, a liver transplant is the only potentially curative option when the patient has developed end-stage liver dis-ease or intractable pruritus. This review aims to delineate the pathogenesis of primary biliary cholangitis and shed light on current therapeutic strategies in the treatment of PBC.

Medford, A., Childs, J., Little, A., Chakraborty, S., Baiocchi, L., Alpini, G., et al. (2023). Emerging Therapeutic Strategies in The Fight Against Primary Biliary Cholangitis. JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 11(4), 949-957 [10.14218/JCTH.2022.00398].

Emerging Therapeutic Strategies in The Fight Against Primary Biliary Cholangitis

Baiocchi, Leonardo;
2023-08-28

Abstract

The liver has a vital role in many metabolic and regulatory processes in the body. Primary biliary cholangitis (PBC), pre-viously known as primary biliary cirrhosis, is a chronic choles-tatic autoimmune disease of the intrahepatic bile ducts asso-ciated with loss of tolerance to mitochondrial antigens. At this time there is no definitive cure for PBC; however, ursodeoxy-cholic acid (UDCA) has been shown to reduce injury when ad-ministered as the first line of treatment. Additional therapeu-tics can be given concurrently or as an alternative to UDCA to manage the symptoms and further curb disease progression. Currently, a liver transplant is the only potentially curative option when the patient has developed end-stage liver dis-ease or intractable pruritus. This review aims to delineate the pathogenesis of primary biliary cholangitis and shed light on current therapeutic strategies in the treatment of PBC.
28-ago-2023
Pubblicato
Rilevanza internazionale
Review
Esperti anonimi
Settore MED/12
English
Biliary epithelia ursodeoxycholic acid
Cholestatic liver disease
Therapeutic approaches
Medford, A., Childs, J., Little, A., Chakraborty, S., Baiocchi, L., Alpini, G., et al. (2023). Emerging Therapeutic Strategies in The Fight Against Primary Biliary Cholangitis. JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 11(4), 949-957 [10.14218/JCTH.2022.00398].
Medford, A; Childs, J; Little, A; Chakraborty, S; Baiocchi, L; Alpini, G; Glaser, S
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/345007
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact